Pyc Therapeutics Limited · ASX:PYC
Pyc Therapeutics — Corporate Update (May 2024)
14 slides from Pyc Therapeutics's corporate update, May 9, 2024
Slide 1: Q2 Investor Update
For personal use only Life-changing science Q2 Investor Update May 2024
Slide 2: Disclaimer
Disclaimer The purpose of this presentation is to provide an update of the business which are outside PYC’s control. Important factors that could cause For personal use only of PYC Therapeutics Limited (ASX:PYC) [‘PYC’]. These slides have been actual results to differ materially from assumptions or
Slide 3: Executive Summary
Executive Summary For personal use only A strong start to 2024 • PYC remains on track to realise its ambition of progressing 3 first-in-class drug candidates with disease modifying potential into human trials this year1 • The Company’s near-term ambition has now progressed to delivering ‘clinical pr
Slide 4: PYC has defined the path to market for its first programs
PYC has defined the path to market for its first 3 programs PYC’s path to market is staged with human data read-outs for first-in-class drugs with disease-modifying potential1 For personal use only Program 2024 2025 2026 2027 2028 RP11 Ph1/2 study (underway) Registrational study NDA Product launch a
Slide 5: PYC has entered the transactional window
PYC has entered the transactional window – creating optionality with respect to access to capital For personal use only “Mid-clinical-stage M&A leading the pack - We are seeing much more M&A this year in Phase 1 and Phase 2 than before. There are fewer platform and Phase 3 deals happening and fewer
Slide 6: RP11 represents an attractive commercial opportunity for PYC
RP11 represents an attractive commercial opportunity for PYC For personal use only “The market opportunity is significant, despite CIDP’s low prevalence in the US of less than one in 100,000 people. Vyvgart Hytrulo could reach up to $1.5 billion in global peak sales by 2030 for CIDP alone, TD Cowen
Slide 7: RP11 Program
For personal use only Life-changing science RP11 Program
Slide 8: RP11 Program – Deep Dive
RP11 Program – Deep Dive Pre-clinical Human Early insights on For personal use only PK/PD Human Efficacy PD1 Safety1 human efficacy1 Untreated RP11 Baseline “The only time to run Phase 3 No treatment emergent studies is when you know they PRPF31 serious adverse events are going to work” Treated with
Slide 9: PYC has refined the inclusion criteria for the SAD and MAD
PYC has refined the inclusion criteria for the SAD and MAD For personal use only The Company is focusing on early-stage patients and visual fields to prioritise patients who are likely to demonstrate the most rapid response to VP-001 in the lead up to the design and execution of the registrational t
Slide 10: ADOA Program
For personal use only Life-changing science ADOA Program
Slide 11: PYC has defined the path to market for its first programs
PYC has defined the path to market for its first 3 programs PYC’s path to market is staged with human data read-outs for first-in-class drugs with disease-modifying potential1 For personal use only Program 2024 2025 2026 2027 2028 RP11 Ph1/2 study (underway) Registrational study NDA Product launch a
Slide 12: ADPKD Program
For personal use only Life-changing science ADPKD Program
Slide 13: There is strong support for the mechanism of PYC's approach in ADPKD
There is strong support for the mechanism of PYC’s approach in ADPKD For personal use only “it remains possible that multiple pathways that are directly regulated by the polycystins concur in the prevention of cyst formation and may need to be concomitantly targeted. Thus, re-expressing the polycyst
Slide 14: The regenerative capacity of the kidney observed in animal models of ADPKD
The regenerative capacity of the kidney observed in animal models of ADPKD presents a tantalising prospect in humans For personal use only “even if one could have hypothesized that re-expressing Pkd genes would slow disease progression, the rapidity and completeness of the reversal are astonishing a